Stay updated with breaking news from Priority Review. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study...
The decision by the FDA is a step closer to omalizumab’s potential approval, making it the potential first medicine to reduce reactions to many different food allergens after accidental exposure.
The FDA has accepted for Priority Review the BLA for V116, an investigational 21-valent pneumococcal conjugate vaccine for adults.
In our coverage of myasthenia gravis this year, the top developments show the effects of COVID-19 continue to be uncovered, a new FDA approval for generalized disease, and assessing patient outcomes following uncontrolled disease and respiratory distress.
The U.S. Food and Drug Administration (FDA) has approved two revolutionary cell-based gene therapies, Casgevy and Lyfgenia, which could be a lifesaver for people dealing with the disease who are